Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Fairmount Funds Management LLC

Q3 2023 · 13F-HR

Fairmount Funds Management LLCholdings as filed

Filed 2023-11-14 · accession 0001104659-23-118043

$831.2M
Reported value
20
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
05464T104AXSMAXSOME THERAPEUTICS INC$163.6M19.7%2,341,238CommonSOLE
670703107NUVLNUVALENT INC$112.7M13.6%2,451,819CommonSOLE
45253H101IMGNEURIMMUNOGEN INC$94.1M11.3%5,929,592CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$62.6M7.54%2,941,176CommonSOLE
N5749R1002GHMERUS N V$44.4M5.34%1,881,345CommonSOLE
G5269C101KINIKSA PHARMACEUTICALS LTD$43.0M5.17%2,474,561CommonSOLE
04016X101ARGXARGENX SE$41.2M4.95%83,747CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$34.7M4.17%3,558,975CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$33.7M4.06%1,142,473CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$29.1M3.50%2,131,369CommonSOLE
45258J102IMVTIMMUNOVANT INC$28.8M3.46%750,000CommonSOLE
75525N107RAYZEBIO INC$27.1M3.26%1,221,904CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$26.4M3.17%1,928,503CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$21.0M2.53%1,369,623CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$19.2M2.31%1,393,329CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$14.2M1.71%1,901,397CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$11.3M1.35%5,163,287CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$10.3M1.23%2,040,000CommonSOLE
23306J101DBV TECHNOLOGIES SA$9.2M1.11%6,781,150CommonSOLE
00773J202SYREAEGLEA BIOTHERAPEUTICS INC$4.6M0.56%378,421CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.